Delcath Registry
Research type
Research Study
Full title
Collection of Safety, Efficacy and Resource Utilization Information in Patients Who Have Received Melphalan PHP with the Delcath Hepatic Delivery System for the Treatment of Unresectable Hepatic Malignancy
IRAS ID
145630
Contact name
Kim Wharton
Contact email
Sponsor organisation
Delcath Systems, Inc
Duration of Study in the UK
2 years, 2 months, 14 days
Research summary
The CHEMOSAT kit containing Gen 2 filters has been used to treat patients since April 2011. This study is designed to collect the treatment outcome in patients who receive this treatment and use experience of the CHEMOSAT Kits by healthcare professionals. The safety and efficacy data from these patients is important in updating the safety profile as well as the risk/benefit of the treatment. The resource utilization information is essential in planning treatment strategy for patients.
REC name
North East - Newcastle & North Tyneside 1 Research Ethics Committee
REC reference
15/NE/0113
Date of REC Opinion
15 Apr 2015
REC opinion
Further Information Favourable Opinion